Literature DB >> 29382958

Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries.

Cuneyt Tegin1, Gulay Tegin1, Rif S El-Mallakh1.   

Abstract

Objective: One of the possible explanations for the antidepressant resistance is tolerance to the effect of increasing synaptic serotonin. Vortioxetine is thought to work through a combination of two pharmacological modes of action: serotonin reuptake inhibition and modification of serotonin receptor activity, in a dose-dependent manner. This mechanism of action allows for examination of the hypothesis that antidepressant non-response may be due to exposure to persistently elevated synaptic amine levels.
Methods: We hypothesized that lower doses of vortioxetine, which exclusively inhibit serotonin reuptake, would not be effective in the setting of prolonged exposure to antidepressants, but higher doses, which interact in various ways to multiple post-synaptic serotonin receptors, would be relatively more effective in the setting of prolonged, prestudy antidepressant exposure. We examined the relationship between Defined Daily Dose (DDD), which is a measure of the extent of antidepressant use in each country, and the minimal effective dose of vortioxetine. Principal Observation: There is a significant relationship between the DDD and effective vortioxetine dose (P = 0.035). Conclusions: In countries with high antidepressant utilization, higher doses of vortioxetine were required, and obverse was true in countries with lower antidepressant utilization. These data support the hypothesis that tolerance to serotonin reuptake inhibition drives poor antidepressant response.

Entities:  

Keywords:  antidepressant tolerance; defined daily dose; vortioxetine

Mesh:

Substances:

Year:  2018        PMID: 29382958      PMCID: PMC5765433     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  32 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse.

Authors:  Alex G Nackenoff; Linda D Simmler; Nicole L Baganz; Alan L Pehrson; Connie Sánchez; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2017-03-20       Impact factor: 4.418

3.  Tachyphylaxis in unipolar major depressive disorder.

Authors:  David A Solomon; Andrew C Leon; Timothy I Mueller; William Coryell; Jedediah J Teres; Michael A Posternak; Lewis L Judd; Jean Endicott; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

Review 4.  Studies of long-term use of antidepressants: how should the data from them be interpreted?

Authors:  Rif S El-Mallakh; Brian Briscoe
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

5.  A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Ioana Florea
Journal:  J Psychopharmacol       Date:  2012-04-09       Impact factor: 4.153

6.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

7.  A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Authors:  Neven Henigsberg; Atul R Mahableshwarkar; Paula Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2012-07       Impact factor: 4.384

8.  A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

Authors:  Rakesh Jain; Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  Int J Neuropsychopharmacol       Date:  2012-09-11       Impact factor: 5.176

9.  Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Christina Kurre Olsen
Journal:  Int Clin Psychopharmacol       Date:  2014-05       Impact factor: 1.659

10.  A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.

Authors:  Stuart A Montgomery; Rebecca Z Nielsen; Lis H Poulsen; Lars Häggström
Journal:  Hum Psychopharmacol       Date:  2014-09       Impact factor: 1.672

View more
  1 in total

1.  Asenapine in the Treatment of Bipolar Depression.

Authors:  Rif S El-Mallakh; Sharon Nuss; Dong Gao; Yonglin Gao; Surriya Colleen Ahmad; Clare Schrodt; Caleb Adler
Journal:  Psychopharmacol Bull       Date:  2020-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.